MEDP · Medpace Holdings Inc
Price
Snapshot
50 fields · last close| Market Cap | $18.49B |
| P/E | 37.29 |
| Float | 22.67M |
| Beta | 1.11 |
| Volatility | 27.8% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 74.8 |
| Price | 681.89 |
| Change | +2.93% |
| Prev Close | 662.48 |
| Open | 614.98 |
| Day Low | 614.98 |
| Day High | 666.65 |
| Avg Vol | 0 |
| Avg $ Vol | $226.6M |
| 52W High | 677.90 |
| 52W Low | 373.00 |
| 52W Pos | 101.3% |
| From High | +0.59% |
| From Low | +82.81% |
| Max DD 1Y | −36.61% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +10.52% |
| SMA 50 | +12.06% |
| SMA 200 | +29.37% |
| RSI (14) | 68.2 |
| Vol 30D | 32.0% |
| Vol 90D | 38.1% |
| 1Y Range | 373–678 |
| Daily bars | 539 |
| Perf Week | +7.44% |
| Perf Month | +5.12% |
| Perf Quarter | +9.35% |
| Perf Half Y | +30.29% |
| Perf Year | +21.69% |
| Perf YTD | +19.42% |
| Prev Day | +2.93% |
| Clavix | B |
| Debt / Eq | 0.36 |
| Curr Ratio | 0.74 |
| Int Cover | 100.5× |
| FCF Margin | 27.0% |
| Rev Growth | +20.0% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 9 / 19 |
Clavix risk grade
regraded every trading dayMEDP grades B, 74.8 of 100. Steadiest on Sector Resilience (68), most exposed on Price Stability (57, mixed). 1 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 9 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| MEDP | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.11 | 1.18 |
| Volatilityannualized | 27.8% | 29.4% |
| Max drawdown, past yearworst peak-to-trough fall | −36.6% | — |
| Typical daily movemedian absolute daily change | 1.11% | — |
| Days beyond ±3%of the last 252 sessions | 32 (13%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| MEDP | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.11 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| MEDP | |
|---|---|
| 1 week | +7.4% |
| 1 month | +5.1% |
| Year to date | +19.4% |
| 1 year | +21.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| MEDP | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 25 Jul |
| Average score0 most bearish, 100 most bullish | 55 |
| Bullish · bearisharticles above 60 · below 40 | 15 · 12 |
| Directionarticles whose tone is improving vs worsening | 15 ↑ 12 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| MEDP | |
|---|---|
| Revenue growthyear over year | +20.0% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openMedpace reported third-quarter profit of $4.84 per share, beating the $4.45 that analysts had expected. That compares to $3.86 per share in the same quarter a year ago. The article is short and does not include a specific revenue figure, though the headline says revenues also beat estimates.
Medpace beat third-quarter earnings forecasts and issued a 2026 earnings outlook above analysts' expectations. Its stock nevertheless slipped late Wednesday; the article gives no specific reason for the decline.
Medpace reported Q3 2026 results showing revenue of $716.0 million for the three months ended September 30, 2026, up 8.5% from $659.9 million in the same quarter a year earlier. The article begins to mention backlog but is cut off before giving that figure.
Medpace's stock is being misread because the market sees its faster cleanup of its backlog of booked work as a sign growth is topping out, when the article argues it actually reflects higher-quality contracts. Q2 revenue rose 17.2% to $707.3M, the EBITDA margin improved underneath pass-through cost effects, and full-year 2026 guidance was raised for revenue, EBITDA, and EPS.
Medpace CEO August Troendle sold 21,966 of his shares on Wednesday, September 30, at an average price of $625.47, for a total of roughly $13.74 million, reducing his direct ownership in the company by about 6%. After the sale he still holds about 338,225 shares, worth around $211.5 million at that same price.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| RVTY | Revvity Inc | B | $17.48B | 74.16 | 1.09 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $16.46B | — | 1.38 | Compare |
| WST | West Pharmaceutical Services Inc | A- | $27.69B | 50.15 | 1.15 | Compare |
| TEM | Tempus AI Inc | D- | $12.23B | — | 2.54 | Compare |
| AVTR | Avantor Inc | B- | $11.67B | — | 0.98 | Compare |
| RGEN | Repligen Corp | B- | $11.43B | 279.84 | 1.13 | Compare |
| TECH | Bio-Techne Corp | B | $11.39B | 62.59 | 1.29 | Compare |
| QGEN | Qiagen NV | B+ | $10.32B | 25.05 | 0.59 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.